| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.794 | 0.004 | 0.794 | Antiadrenergic | 0.277 0.015 DBMET03228 | ||
| 0.794 | 0.004 | 0.794 | Adrenaline antagonist | 0.274 0.015 DBMET03228 | ||
| 0.673 | 0.017 | 0.788 | Cyclophilin D inhibitor | 0.788 0.007 DBMET03228 | DBMET03228 | |
| 0.557 | 0.004 | 0.557 | Lipid peroxidase inhibitor | 0.503 0.005 DBMET03228 | ||
| 0.539 | 0.001 | 0.539 | Alpha 1b adrenoreceptor agonist | 0.313 0.001 DBMET03228 | ||
| 0.498 | 0.004 | 0.498 | Alpha 2b adrenoreceptor antagonist | |||
| 0.464 | 0.001 | 0.464 | Alpha 1a adrenoreceptor agonist | 0.247 0.002 DBMET03228 | ||
| 0.453 | 0.005 | 0.453 | 5-Lipoxygenase inhibitor | 0.1 0.064 DBMET03228 | ||
| 0.44 | 0.001 | 0.44 | Alpha 2a adrenoreceptor agonist | |||
| 0.436 | 0 | 0.436 | Alpha 1L adrenoreceptor agonist | 0.24 0.001 DBMET03228 | ||
| 0.461 | 0.037 | 0.461 | Vasodilator, peripheral | 0.353 0.073 DBMET03228 | ||
| 0.437 | 0.029 | 0.437 | Lipoxygenase inhibitor | |||
| 0.432 | 0.03 | 0.563 | Antioxidant | 0.563 0.014 DBMET03228 | DBMET03228 | |
| 0.406 | 0.005 | 0.406 | Alpha 2a adrenoreceptor antagonist | |||
| 0.388 | 0.001 | 0.388 | Alpha 2d adrenoreceptor agonist | 0.111 0.003 DBMET03228 | ||
| 0.346 | 0.003 | 0.346 | Alpha 2 adrenoreceptor agonist | |||
| 0.345 | 0.004 | 0.345 | Alpha adrenoreceptor agonist | |||
| 0.36 | 0.021 | 0.36 | ErbB-1 antagonist | |||
| 0.37 | 0.033 | 0.519 | Hypoglycemic | 0.519 0.014 DBMET03228 | DBMET03228 | |
| 0.446 | 0.112 | 0.67 | Antiinflammatory | 0.67 0.037 DBMET03228 | DBMET03228 | |
| 0.337 | 0.006 | 0.337 | Alpha 2 adrenoreceptor antagonist | |||
| 0.38 | 0.054 | 0.568 | Cholesterol antagonist | 0.568 0.023 DBMET03228 | DBMET03228 | |
| 0.323 | 0.005 | 0.323 | Alpha 2c adrenoreceptor antagonist | |||
| 0.373 | 0.07 | 0.678 | Transcription factor NF kappa B inhibitor | 0.678 0.023 DBMET03228 | DBMET03228 | |
| 0.326 | 0.028 | 0.403 | Anesthetic general | 0.403 0.016 DBMET03228 | DBMET03228 | |
| 0.359 | 0.083 | 0.373 | Antiobesity | 0.373 0.076 DBMET03228 | DBMET03228 | |
| 0.335 | 0.063 | 0.439 | Apoptosis antagonist | 0.439 0.029 DBMET03228 | DBMET03228 | |
| 0.269 | 0.001 | 0.269 | Alpha 1d adrenoreceptor agonist | |||
| 0.306 | 0.047 | 0.308 | Hypolipemic | 0.308 0.046 DBMET03228 | DBMET03228 | |
| 0.308 | 0.067 | 0.474 | Spasmolytic | 0.474 0.027 DBMET03228 | DBMET03228 | |
| 0.253 | 0.019 | 0.253 | Insulin secretagoues | 0.247 0.02 DBMET03228 | ||
| 0.288 | 0.055 | 0.445 | Free radical scavenger | 0.445 0.022 DBMET03228 | DBMET03228 | |
| 0.225 | 0.005 | 0.225 | Adrenaline agonist | |||
| 0.211 | 0.006 | 0.211 | 5 Hydroxytryptamine 1D antagonist | |||
| 0.206 | 0.003 | 0.206 | Alpha 2d adrenoreceptor antagonist | 0.156 0.007 DBMET03228 | ||
| 0.227 | 0.026 | 0.227 | Nav1.2 sodium channel blocker | |||
| 0.347 | 0.155 | 0.347 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | |||
| 0.184 | 0.007 | 0.184 | Alpha 1 adrenoreceptor agonist | |||
| 0.2 | 0.034 | 0.2 | Cyclooxygenase 1 inhibitor | 0.108 0.092 DBMET03228 | ||
| 0.201 | 0.042 | 0.201 | Acetylcholine M1 receptor antagonist | |||
| 0.171 | 0.013 | 0.171 | 5 Hydroxytryptamine 1 agonist | |||
| 0.16 | 0.002 | 0.16 | Imidazoline I1 receptor antagonist | |||
| 0.17 | 0.012 | 0.17 | Alpha 1d adrenoreceptor antagonist | |||
| 0.187 | 0.03 | 0.187 | Alpha adrenoreceptor antagonist | |||
| 0.167 | 0.01 | 0.167 | Cyclin B3 inhibitor | |||
| 0.153 | 0.002 | 0.153 | Alpha 2b adrenoreceptor agonist | |||
| 0.194 | 0.046 | 0.194 | Diuretic | 0.171 0.06 DBMET03228 | ||
| 0.162 | 0.019 | 0.162 | 5 Hydroxytryptamine agonist | |||
| 0.174 | 0.031 | 0.174 | Adenylate cyclase stimulant | |||
| 0.141 | 0.002 | 0.141 | Parathyroid hormone antagonist | 0.102 0.003 DBMET03228 | ||
| 0.143 | 0.014 | 0.143 | 5 Hydroxytryptamine 1B antagonist | |||
| 0.218 | 0.089 | 0.254 | Platelet antagonist | 0.254 0.071 DBMET03228 | DBMET03228 | |
| 0.15 | 0.022 | 0.15 | Alpha 1b adrenoreceptor antagonist | |||
| 0.127 | 0.003 | 0.127 | Kallikrein 7 inhibitor | 0.093 0.006 DBMET03228 | ||
| 0.288 | 0.168 | 0.288 | Calcium channel L-type activator | |||
| 0.132 | 0.012 | 0.154 | Glycine receptor antagonist | 0.154 0.007 DBMET03228 | DBMET03228 | |
| 0.12 | 0.013 | 0.12 | 5 Hydroxytryptamine 1A agonist | |||
| 0.11 | 0.004 | 0.11 | Adenine nucleotide translocase inhibitor | 0.101 0.004 DBMET03228 | ||
| 0.163 | 0.06 | 0.163 | Cyclooxygenase inhibitor | |||
| 0.144 | 0.045 | 0.144 | Vanilloid 1 agonist | 0.126 0.074 DBMET03228 | ||
| 0.105 | 0.009 | 0.105 | 5 Hydroxytryptamine 2 agonist | |||
| 0.251 | 0.155 | 0.267 | Histamine release inhibitor | 0.267 0.143 DBMET03228 | DBMET03228 | |
| 0.248 | 0.156 | 0.248 | GABA C receptor rho-3 antagonist | |||
| 0.206 | 0.115 | 0.379 | DNA synthesis inhibitor | 0.379 0.025 DBMET03228 | DBMET03228 | |
| 0.099 | 0.015 | 0.099 | NMDA 2B receptor antagonist | |||
| 0.083 | 0.005 | 0.083 | 5 Hydroxytryptamine 2B agonist | |||
| 0.157 | 0.081 | 0.157 | Arachidonic acid antagonist | |||
| 0.156 | 0.081 | 0.244 | Interleukin 6 antagonist | 0.244 0.024 DBMET03228 | DBMET03228 | |
| 0.113 | 0.039 | 0.113 | Alpha 1 adrenoreceptor antagonist | |||
| 0.096 | 0.023 | 0.096 | Glycine receptor agonist | 0.07 0.055 DBMET03228 | ||
| 0.131 | 0.059 | 0.131 | Papain-like protease (SARS coronavirus) inhibitor | |||
| 0.098 | 0.027 | 0.098 | Leukotriene synthesis inhibitor | |||
| 0.118 | 0.05 | 0.118 | Electron transport complex I inhibitor | |||
| 0.081 | 0.013 | 0.081 | NMDA receptor subunit 3B antagonist | |||
| 0.088 | 0.022 | 0.088 | Beta adrenoreceptor antagonist | |||
| 0.099 | 0.034 | 0.099 | Vanilloid agonist | 0.09 0.046 DBMET03228 | ||
| 0.178 | 0.113 | 0.189 | Cyclic AMP phosphodiesterase inhibitor | 0.189 0.102 DBMET03228 | DBMET03228 | |
| 0.117 | 0.056 | 0.117 | Ferrochelatase inhibitor | |||
| 0.231 | 0.171 | 0.231 | Calcium channel activator | |||
| 0.082 | 0.024 | 0.082 | Maillard reaction inhibitor | |||
| 0.277 | 0.22 | 0.407 | Caspase 9 stimulant | 0.407 0.107 DBMET03228 | DBMET03228 | |
| 0.065 | 0.009 | 0.065 | AMPA 4 receptor antagonist | |||
| 0.094 | 0.039 | 0.094 | Alpha 1a adrenoreceptor antagonist | |||
| 0.116 | 0.064 | 0.116 | TRPA1 agonist | |||
| 0.055 | 0.003 | 0.055 | Alpha 2c adrenoreceptor agonist | |||
| 0.09 | 0.041 | 0.09 | Estrogen-related receptor beta agonist | |||
| 0.112 | 0.064 | 0.112 | Activin receptor-like kinase 4 inhibitor | |||
| 0.12 | 0.074 | 0.12 | Nav1.3 sodium channel blocker | |||
| 0.119 | 0.075 | 0.119 | Cholinergic antagonist | |||
| 0.072 | 0.029 | 0.072 | Cyclin B1 inhibitor | |||
| 0.045 | 0.003 | 0.045 | Thyroid hormone alpha agonist | 0.017 0.01 DBMET03228 | ||
| 0.103 | 0.063 | 0.103 | Nav1.1 sodium channel blocker | |||
| 0.041 | 0.003 | 0.041 | Imidazoline I2 receptor antagonist | |||
| 0.065 | 0.027 | 0.065 | Cyclin B2 inhibitor | |||
| 0.071 | 0.036 | 0.071 | 5 Hydroxytryptamine 2A agonist | |||
| 0.057 | 0.026 | 0.057 | Alpha 1L adrenoreceptor antagonist | |||
| 0.078 | 0.048 | 0.078 | Acetylcholine M4 receptor antagonist | |||
| 0.038 | 0.009 | 0.038 | Thiazolidinedione | |||
| 0.109 | 0.08 | 0.109 | Acetylcholine antagonist | |||
| 0.06 | 0.031 | 0.06 | Pregnane X receptor antagonist | |||
| 0.135 | 0.106 | 0.135 | CF transmembrane conductance regulator agonist | |||
| 0.123 | 0.097 | 0.123 | Farnesoid X receptor antagonist | |||
| 0.042 | 0.017 | 0.042 | Prostacyclin antagonist | |||
| 0.047 | 0.021 | 0.047 | NMDA receptor subunit 3A antagonist | |||
| 0.034 | 0.009 | 0.034 | Thyroid hormone agonist | |||
| 0.084 | 0.06 | 0.084 | NMDA receptor antagonist | |||
| 0.102 | 0.081 | 0.102 | 5 Hydroxytryptamine 2B antagonist | |||
| 0.125 | 0.106 | 0.365 | NOS3 expression enhancer | 0.365 0.01 DBMET03228 | DBMET03228 | |
| 0.056 | 0.037 | 0.056 | Cyclin B inhibitor | |||
| 0.028 | 0.011 | 0.028 | Phosphodiesterase IX inhibitor | |||
| 0.059 | 0.043 | 0.059 | Acetylcholine M5 receptor antagonist | |||
| 0.063 | 0.047 | 0.063 | Interferon inducer | |||
| 0.051 | 0.035 | 0.051 | Beta 2 adrenoreceptor antagonist | |||
| 0.067 | 0.057 | 0.067 | 5 Hydroxytryptamine 1 antagonist | |||
| 0.075 | 0.066 | 0.075 | 5 Hydroxytryptamine 2C antagonist | |||
| 0.1 | 0.091 | 0.1 | Acetylcholine muscarinic antagonist | |||
| 0.121 | 0.113 | 0.126 | CC chemokine 6 receptor antagonist | 0.126 0.085 DBMET03228 | DBMET03228 | |
| 0.05 | 0.043 | 0.05 | Nicotinic receptor alpha7 subunit antagonist | |||
| 0.024 | 0.018 | 0.024 | Kainate receptor 4 antagonist | |||
| 0.043 | 0.038 | 0.043 | Kallikrein inhibitor | |||
| 0.026 | 0.021 | 0.026 | Motilin receptor antagonist | |||
| 0.097 | 0.092 | 0.097 | Cholesterol synthesis inhibitor | |||
| 0.015 | 0.011 | 0.015 | Thyroid hormone alpha antagonist | |||
| 0.125 | 0.121 | 0.146 | Interferon gamma antagonist | 0.146 0.083 DBMET03228 | DBMET03228 | |
| 0.044 | 0.04 | 0.044 | Mineralocorticoid receptor antagonist | |||
| 0.072 | 0.067 | 0.072 | Interferon agonist | |||
| 0.02 | 0.016 | 0.02 | Retinoid X beta receptor agonist | |||
| 0.023 | 0.019 | 0.023 | Phosphodiesterase 9A inhibitor | |||
| 0.18 | 0.176 | 0.18 | Tyrosine 3 hydroxylase inhibitor | |||
| 0.026 | 0.023 | 0.026 | Retinoid X gamma receptor antagonist | |||
| 0.083 | 0.08 | 0.083 | ABCA1 expression enhancer | |||
| 0.045 | 0.043 | 0.045 | Dopamine beta hydroxylase inhibitor | |||
| 0.111 | 0.109 | 0.111 | Nav1.6 sodium channel blocker | |||
| 0.021 | 0.019 | 0.021 | Retinoid X gamma receptor agonist | |||
| 0.178 | 0.207 | 0.217 | Caspase 3 stimulant | 0.217 0.146 DBMET03228 | DBMET03228 | |
| 0.173 | 0.216 | 0.52 | Antithrombotic | 0.52 0.026 DBMET03228 | DBMET03228 | |
| 0.067 | 0.112 | 0.131 | NADH dehydrogenase inhibitor | 0.131 0.023 DBMET03228 | DBMET03228 | |
| 0.134 | 0.182 | 0.224 | Vasodilator | 0.224 0.086 DBMET03228 | DBMET03228 | |
| 0.147 | 0.207 | 0.179 | RNA-directed DNA polymerase inhibitor | 0.179 0.135 DBMET03228 | DBMET03228 | |
| 0.16 | 0.225 | 0.31 | Vasodilator, coronary | 0.31 0.08 DBMET03228 | DBMET03228 | |
| 0.072 | 0.138 | 0.134 | Beta amyloid protein antagonist | 0.134 0.054 DBMET03228 | DBMET03228 | |
| 0.095 | 0.163 | 0.18 | Mannose-6-phosphate isomerase inhibitor | 0.18 0.043 DBMET03228 | DBMET03228 | |
| 0.106 | 0.18 | 0.33 | Hepatoprotectant | 0.33 0.022 DBMET03228 | DBMET03228 | |
| 0.014 | 0.087 | 0.026 | Sodium/glucose cotransporter inhibitor | 0.026 0.017 DBMET03228 | DBMET03228 | |
| 0.033 | 0.109 | 0.061 | Glucose-6-phosphate translocase inhibitor | 0.061 0.022 DBMET03228 | DBMET03228 | |
| 0.056 | 0.147 | 0.132 | Expectorant | 0.132 0.044 DBMET03228 | DBMET03228 | |
| 0.07 | 0.164 | 0.121 | Alpha-N-acetylglucosaminidase inhibitor | 0.121 0.077 DBMET03228 | DBMET03228 | |
| 0.032 | 0.15 | 0.076 | Na+ K+ transporting ATPase inhibitor | 0.076 0.055 DBMET03228 | DBMET03228 | |
| 0.023 | 0.16 | 0.059 | Alpha-mannosidase inhibitor | 0.059 0.028 DBMET03228 | DBMET03228 | |
| 0.053 | 0.201 | 0.149 | Amylase inhibitor | 0.149 0.065 DBMET03228 | DBMET03228 | |
| 0.082 | 0.232 | 0.227 | Nitric oxide antagonist | 0.227 0.058 DBMET03228 | DBMET03228 | |
| 0.02 | 0.179 | 0.098 | Antineoplastic antibiotic | 0.098 0.047 DBMET03228 | DBMET03228 | |
| 0.015 | 0.174 | 0.046 | Mannosidase inhibitor | 0.046 0.031 DBMET03228 | DBMET03228 | |
| 0.045 | 0.207 | 0.125 | UDP-glucose 4-epimerase inhibitor | 0.125 0.04 DBMET03228 | DBMET03228 | |
| 0.126 | 0.323 | 0.209 | Toll-Like receptor agonist | 0.209 0.19 DBMET03228 | DBMET03228 | |
| 0.132 | 0.33 | 0.518 | Antibacterial | 0.518 0.036 DBMET03228 | DBMET03228 | |
| 0.068 | 0.271 | 0.15 | Hexokinase inhibitor | 0.15 0.079 DBMET03228 | DBMET03228 | |
| 0.034 | 0.282 | 0.059 | Lipocortins synthesis agonist | 0.059 0.039 DBMET03228 | DBMET03228 | |
| 0.047 | 0.308 | 0.416 | Angiogenesis stimulant | 0.416 0.019 DBMET03228 | DBMET03228 | |
| 0.079 | 0.364 | 0.227 | Alpha-glucosidase inhibitor | 0.227 0.201 DBMET03228 | DBMET03228 | |
| 0.05 | 0.35 | 0.291 | Immunostimulant | 0.291 0.081 DBMET03228 | DBMET03228 | |
| 0.056 | 0.38 | 0.154 | Hemostatic | 0.154 0.063 DBMET03228 | DBMET03228 | |
| 0.047 | 0.391 | 0.176 | Platelet adhesion inhibitor | 0.176 0.085 DBMET03228 | DBMET03228 | |
| 0.037 | 0.421 | 0.114 | Cyclooxygenase 3 inhibitor | 0.114 0.084 DBMET03228 | DBMET03228 | |
| 0.012 | 0.404 | 0.06 | Protein 50S ribosomal subunit inhibitor | 0.06 0.031 DBMET03228 | DBMET03228 | |
| 0.096 | 0.499 | 0.322 | Interleukin 2 agonist | 0.322 0.06 DBMET03228 | DBMET03228 | |
| 0.056 | 0.459 | 0.516 | Immunosuppressant | 0.516 0.029 DBMET03228 | DBMET03228 | |
| 0.012 | 0.462 | 0.052 | Antibiotic Aminoglycoside-like | 0.052 0.012 DBMET03228 | DBMET03228 | |
| 0.084 | 0.562 | 0.252 | Peptidyltransferase inhibitor | 0.252 0.049 DBMET03228 | DBMET03228 | |
| 0.013 | 0.503 | 0.088 | Topoisomerase I inhibitor | 0.088 0.081 DBMET03228 | DBMET03228 | |
| 0.019 | 0.515 | 0.147 | Thrombolytic | 0.147 0.084 DBMET03228 | DBMET03228 | |
| 0.006 | 0.507 | 0.188 | Selectin antagonist | 0.188 0.012 DBMET03228 | DBMET03228 | |
| 0.05 | 0.643 | 0.335 | Apoptosis agonist | 0.335 0.148 DBMET03228 | DBMET03228 | |
| 0.027 | 0.669 | 0.107 | Transcription factor NF kappa B stimulant | 0.107 0.033 DBMET03228 | DBMET03228 | |
| 0.019 | 0.696 | 0.1 | Toll-Like receptor 4 antagonist | 0.1 0.07 DBMET03228 | DBMET03228 | |
| 0.011 | 0.825 | 0.088 | Thioredoxin inhibitor | 0.088 0.065 DBMET03228 | DBMET03228 | |
| 0.006 | 0.941 | 0.369 | Immunomodulator | 0.369 0.054 DBMET03228 | DBMET03228 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |